000166761 001__ 166761
000166761 005__ 20240229133529.0
000166761 0247_ $$2doi$$a10.1002/ijc.33470
000166761 0247_ $$2pmid$$apmid:33433939
000166761 0247_ $$2ISSN$$a0020-7136
000166761 0247_ $$2ISSN$$a1097-0215
000166761 0247_ $$2altmetric$$aaltmetric:97590128
000166761 037__ $$aDKFZ-2021-00100
000166761 041__ $$aeng
000166761 082__ $$a610
000166761 1001_ $$00000-0002-1931-1349$$aO'Brien, Katie M$$b0
000166761 245__ $$aGenital powder use and risk of uterine cancer: A pooled analysis of prospective studies.
000166761 260__ $$aBognor Regis$$bWiley-Liss$$c2021
000166761 3367_ $$2DRIVER$$aarticle
000166761 3367_ $$2DataCite$$aOutput Types/Journal article
000166761 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1619610984_10127
000166761 3367_ $$2BibTeX$$aARTICLE
000166761 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166761 3367_ $$00$$2EndNote$$aJournal Article
000166761 500__ $$a2021 Jun 1;148(11):2692-2701
000166761 520__ $$aWhen powder is applied to the genital area, it has the potential to reach internal reproductive organs and promote carcinogenesis by irritating and inflaming exposed tissues. While many studies have considered the association between genital powder use and ovarian cancer risk, the relationship between genital powder use and uterine cancer is less well-studied. We pooled data from four large, prospective cohorts (the Nurses' Health Study, the Nurses' Health Study II, the Sister Study, and the Women's Health Initiative - Observational Study). We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CI), adjusting for pre-specified confounders. In total, 209 185 women were included, with 37% reporting ever genital powder use. Over a mean 14.5 years of follow-up, 3272 invasive uterine cancers were diagnosed. There was no overall association between ever genital powder use and uterine cancer (HR = 1.01, 95% CI: 0.94-1.09), with little difference observed for frequent (≥1 times/week) vs never use (HR = 1.05, 95% CI: 0.95-1.16; p-for-trend = 0.46). Long-term use (>20 years; HR = 1.12, 95% CI: 0.96-1.31; p-for-trend = 0.14) was associated with a small, but not statistically significant, increase in risk, compared to never use. There were not clear differences by uterine cancer histologic subtypes or across strata of relevant covariates, including race/ethnicity, follow-up time, menopausal status and body mass index. The results of this large, pooled analysis do not support a relationship between use of genital powder and uterine cancer, though the positive associations observed for long-term use may merit further consideration. This article is protected by copyright. All rights reserved.
000166761 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000166761 588__ $$aDataset connected to CrossRef, PubMed,
000166761 650_7 $$2Other$$aUterine cancer
000166761 650_7 $$2Other$$aendometrial cancer
000166761 650_7 $$2Other$$agenital powder
000166761 650_7 $$2Other$$atalc
000166761 7001_ $$00000-0002-6986-7046$$aTworoger, Shelley S$$b1
000166761 7001_ $$aHarris, Holly R$$b2
000166761 7001_ $$00000-0002-1539-6090$$aTrabert, Britton$$b3
000166761 7001_ $$aWeinberg, Clarice R$$b4
000166761 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renee T$$b5$$udkfz
000166761 7001_ $$aD'Aloisio, Aimee A$$b6
000166761 7001_ $$aKaunitz, Andrew M$$b7
000166761 7001_ $$00000-0003-1251-0836$$aWentzensen, Nicolas$$b8
000166761 7001_ $$aSandler, Dale P$$b9
000166761 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.33470$$gp. ijc.33470$$n11$$p2692-2701$$tInternational journal of cancer$$v148$$x1097-0215$$y2021
000166761 909CO $$ooai:inrepo02.dkfz.de:166761$$pVDB
000166761 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000166761 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000166761 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000166761 9141_ $$y2021
000166761 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-08-32$$wger
000166761 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2020-08-32$$wger
000166761 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2018$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-32
000166761 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-32
000166761 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000166761 980__ $$ajournal
000166761 980__ $$aVDB
000166761 980__ $$aI:(DE-He78)C020-20160331
000166761 980__ $$aUNRESTRICTED